[{"from": "human", "value": "What can you tell me about this molecule? [C][C][=C][Branch2][Ring1][P][S][C][=C][Ring1][Branch1][N][=C][Branch1][=N][N][=C][Ring1][=Branch1][N][C][C][O][C][C][Ring1][=Branch1][C][=C][N][=C][Branch1][Branch1][N][=C][Ring1][=Branch1][N][C][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=Branch1][C][=O][C@H1][Branch1][C][C][O]"}, {"from": "gpt", "value": "The molecule is an orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Apitolisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion."}]